Shares of Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA – Get Free Report) crossed above its 50 day moving average during trading on Tuesday. The stock has a 50 day moving average of $0.11 and traded as high as $0.1349. Hepion Pharmaceuticals shares last traded at $0.1150, with a volume of 32,939 shares.
Hepion Pharmaceuticals Stock Down 13.0%
The business’s 50-day simple moving average is $0.11 and its 200 day simple moving average is $0.07. The firm has a market capitalization of $1.14 million, a P/E ratio of -0.02 and a beta of 1.52.
Hepion Pharmaceuticals (NASDAQ:HEPA – Get Free Report) last posted its quarterly earnings results on Monday, November 16th. The company reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($200.00) by $199.94.
About Hepion Pharmaceuticals
Hepion Pharmaceuticals was a clinical-stage biopharmaceutical company focused on developing treatments for chronic liver diseases. Its research centered on rencofilstat, an investigational oral cyclophilin inhibitor studied for conditions including nonalcoholic steatohepatitis (NASH) and liver fibrosis. The company was formerly known as ContraVir Pharmaceuticals and adopted the Hepion name in 2019. Its work included clinical development of rencofilstat; the candidate was investigational and had not been approved as a treatment.
Recommended Stories
- Five stocks we like better than Hepion Pharmaceuticals
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for Hepion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hepion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
